阅读说明：本技术 一种靶向fgfr4的亲和肽及其应用 (FGFR 4-targeted affinity peptide and application thereof ) 是由 顾月清 连晨 韩智豪 许昊然 耿轩 于 2021-09-18 设计创作，主要内容包括：本发明公开了一种靶向FGFR4的亲和肽及其应用。肿瘤靶向肽,包括YQGF-1：Ac-IIe-Asp-Pro-Asp-Gly-Tyr-Asn-His-NH2等6条多肽。本发明开发了一系列新的模拟FGF19(成纤维细胞生长因子19)的高亲和力的多肽,可用于靶向成纤维细胞生长因子受体4(FGFR4)。利用FGFR4受体在肿瘤中高表达,基于YQGF-X(X＝1-6)多肽与FGFR4受体特异性结合的原理,可用于FGFR4高表达肿瘤的早期诊断。YQGF-X(X＝1-6)系列多肽可以和肿瘤细胞特异性结合,经活体光学成像和结果证实对多种肿瘤具有优异的显像效果,包括肝癌、乳腺癌、宫颈癌及结直肠癌等。(The invention discloses an affinity peptide targeting FGFR4 and application thereof. A tumor targeting peptide comprising YQGF-1: and 6 polypeptides such as Ac-IIe-Asp-Pro-Asp-Gly-Tyr-Asn-His-NH 2. The invention develops a series of novel high-affinity polypeptides simulating FGF19 (fibroblast growth factor 19) and can be used for targeting fibroblast growth factor receptor 4(FGFR 4). The FGFR4 receptor is highly expressed in tumors, and can be used for early diagnosis of FGFR4 highly expressed tumors based on the principle that YQGF-X (X ═ 1-6) polypeptide is specifically combined with FGFR4 receptor. YQGF-X (X-1-6) series polypeptide can be specifically combined with tumor cells, and has excellent development effect on various tumors including liver cancer, breast cancer, cervical cancer, colorectal cancer and the like through in-vivo optical imaging and results.)

1. A tumor targeting peptide, characterized by being selected from any one of the following polypeptides:

YQGF-1：Ac-IIe-Asp-Pro-Asp-Gly-Tyr-Asn-His-NH2；

YQGF-2:Ac-IIe-Arg-Pro-Asp-Gly-Tyr-Asn-Val-NH2；

YQGF-3：Ac-Phe-Glu-Glu-Glu-IIe-Arg-Pro-Asp-Gly-Tyr-Asn-Val-Tyr-Arg-Ser-Glu-NH2；

YQGF-4：Ac-IIe-homoArg-Pro-Asp-Gly-Tyr-Asn-Val-NH2；

YQGF-5：Ac-IIe-Arg-Pro-Asp-Gly-Tyr-Asn-Nva-NH2；

YQGF-6：Ac-IIe-D-Asp-Pro-Asp-Gly-Tyr-Asn-His-NH2；

wherein homoArg is homoarginine, Nva is norvaline, and D-Asp is D-aspartic acid.

2. Use of a tumor targeting peptide according to claim 1 for the preparation of a reagent for the diagnosis, treatment or tracking of tumors.

3. Use according to claim 2, characterized in that the tumor targeting peptide according to any of claim 1 is used for the preparation of a fluorescence imaging of tumors or for the preparation of radionuclide imaging agents.

4. A tumor targeting probe characterized by the general formula:

M-L-YQGF-X, or M-YQG-X,

wherein M represents a light label or a radionuclide label;

l is a linking group;

YQGF-X is any one of the polypeptides according to claim 1.

5. The probe of claim 4, wherein the optical label is selected from the group consisting of organic chromophore-containing compounds, organic fluorophores, light absorbing compounds, light reflecting compounds, light scattering compounds, and bioluminescent molecules; the organic fluorophore is preferably near infrared fluorescent dye, and further preferably near infrared fluorescent dye MPA, IRDye800, Cy7.5 and Cy5.5.

6. The modified polypeptide according to claim 4, characterized in that said radionuclide is selected from the group consisting of^99mTc、⁶⁸Ga，⁶⁴Cu，⁶⁷Ga，⁹⁰Y，¹¹¹In or¹⁷⁷Lu、¹²⁵I。

7. The probe according to claim 4, wherein L is selected from the group consisting of azidovaleric acid, propiolic acid, polyethylene glycol, 1,4, 7-triazacyclononane-1, 4, 7-triacetic acid, 7- [ (4-hydroxypropyl) methylene ] -1,4, 7-triazacyclononane-1, 4-diacetic acid, 1,4,7, 10-tetraazacyclododecane-1, 4,7, 10-tetraacetic acid, mercaptoacetyltriglycine, MAG2, N3S, N2S2 ligand, diethyl triaminepentaacetic acid, 1, 4-succinic acid, 5-aminopentanoic acid, polyethyleneimine, 6-hydrazinopyridine-3-carboxylic acid, benzyl bromoformate, N- (2-aminoacetic acid) maleimide or combination thereof.

8. A probe according to claim 4 characterised in that L is selected from any one or more of 6-aminocaproic acid, PEG4, PEG 6, HYNIC-PEG4 or HYNIC.

9. Use of the tumor-targeting probe of any one of claims 4 to 8 for the preparation of an imaging agent for tumor diagnosis; preferably in the preparation of a reagent for precise localization of tumor boundaries and intra-operative image-guided imaging or for radionuclide imaging.

10. Use of the tumor targeting peptide of claim 1 in the preparation of a tumor targeting medicament.

Technical Field

The invention belongs to the field of biomedical engineering, and particularly relates to an affinity peptide targeting FGFR4 and application thereof.

Background

Malignant tumors seriously threaten human health. Early diagnosis and treatment of tumors are key to improving the cure rate and improving the quality of life of patients. For tumors, the conventional diagnostic imaging techniques at present mainly include B-mode ultrasound, CT and MRI, which achieve diagnostic results by displaying the functional changes of tissues, and have good application values, but with the continuous improvement of clinical requirements on tumor diagnosis, these conventional detection means gradually fail to meet the detection requirements in differential diagnosis, whole-body staging and early curative effect evaluation. Among the many detection methods, molecular probes are used as powerful tools for analytical sensing and optical imaging, and can directly perform visual analysis on biological analytes at the molecular level and provide useful information for complex biological structures and processes. The basic imaging principle of the molecular probe is to introduce the prepared fluorescent probe into living tissue, to make the labeled molecular probe interact with target molecules, and then to detect the information emitted by the molecular probe by using a proper imaging system. Therefore, the screening and optimization of the tumor-targeted polypeptide can be used for developing a new molecular imaging medicament for the diagnosis, staging and operation guidance of tumors, and can find more tiny lesions to achieve the aim of early diagnosis.

The FGFR (fibroblast growth factor receptor) tyrosine kinase family includes FGFR1, FGFR2, FGFR3, and FGFR4, which consists of an extracellular variation region, a conserved region binding heparan sulfate proteoglycan, an FGF binding region, a single transmembrane region, and an intracellular tyrosine kinase region. Most FGFs form complexes with FGFRs and heparin with the help of the co-receptor Klotho, resulting in autophosphorylation of conformationally altered FGFR intracellular kinase regions to activate the STAT3 signaling pathway. Autophosphorylated FGFR also phosphorylates its aptamer protein FRS2 α, activating the Grb2/Sos1 complex to initiate downstream MAPK and PI3K/AKT signaling through association with primarily cell motility and survival. Among FGFRs, FGFR4 is expressed only in limited amounts in normal human tissue organs, but is expressed at higher levels in positive tumors. Therefore, the FGFR4 receptor can become a target point for tumor specific imaging.

FGF (fibroblast growth factor) signal molecules are not only important for the growth, survival, differentiation and vascularization of normal cells, but also play an important role in the occurrence and development of tumors. 10 of the more than 20 FGF members discovered to date bind FGFR4, with only FGF19 specifically binding FGFR 4. FGF19 is an endocrine growth factor that binds to the specific receptor FGFR4 and requires activation of downstream multiple signaling pathways such as sustained activation of PI3K/AKT, PLC γ/DAG/PKC, RAS/RAF/MAPK, and GSK/β -catenin via β Klotho-forming complexes in Klotho family proteins, mediating cancer cell proliferation, anti-apoptosis, angiogenesis, drug resistance, and epithelial-mesenchymal transition (EMT) for metastasis. Therefore, the FGF19-FGFR4 signaling pathway is considered to be closely related to various tumors and is an ideal target for specific tumor imaging.

Disclosure of Invention

The invention aims to provide a polypeptide and a sequence capable of targeting fibroblast growth factor receptor 4(FGFR4), so that the polypeptide and the sequence can be used for in vivo diagnosis of tumors with high FGFR4 receptor expression and can be used for preparing novel targeted drug carriers.

The invention also aims to provide several tumor-specific targeting fluorescent probes.

The invention also aims to provide application of the polypeptide and the probe.

The purpose of the invention can be realized by the following technical scheme:

a tumor targeting peptide selected from any one of the following polypeptides:

YQGF-1：Ac-IIe-Asp-Pro-Asp-Gly-Tyr-Asn-His-NH2；

YQGF-2:Ac-IIe-Arg-Pro-Asp-Gly-Tyr-Asn-Val-NH2；

YQGF-3：Ac-Phe-Glu-Glu-Glu-IIe-Arg-Pro-Asp-Gly-Tyr-Asn-Val-Tyr-Arg-Ser-Glu-NH2；

YQGF-4：Ac-IIe-homoArg-Pro-Asp-Gly-Tyr-Asn-Val-NH2；

YQGF-5：Ac-IIe-Arg-Pro-Asp-Gly-Tyr-Asn-Nva-NH2；

YQGF-6：Ac-IIe-D-Asp-Pro-Asp-Gly-Tyr-Asn-His-NH2；

wherein homoArg is homoarginine, Nva is norvaline, and D-Asp is D-aspartic acid.

The tumor targeting peptide is applied to the preparation of a reagent for tumor diagnosis, treatment or tracing.

As a preferred choice of the invention, the tumor targeting peptide of the invention is applied to the preparation of a tumor diagnosis imaging agent; preferably in the preparation of a reagent for precise localization of tumor boundaries and intra-operative image-guided imaging or for radionuclide imaging.

A tumor targeting probe having the general formula:

M-L-YQGF-X, or M-YQG-X,

wherein M represents a light label or a radionuclide label;

l is a linking group;

YQGF-X is any one of the polypeptides according to claim 1.

The optical label is selected from the group consisting of organic chromophore-containing compounds, organic fluorophores, light absorbing compounds, light reflecting compounds, light scattering compounds, and bioluminescent molecules.

As a further preferred embodiment of the present invention, the organic fluorophore is a near infrared fluorescent dye, preferably selected from the group consisting of near infrared fluorescent dyes MPA, IRDye800, cy7.5, and cy5.5; further preferably MPA.

The radionuclide is selected from^99mTc、⁶⁸Ga，⁶⁴Cu，⁶⁷Ga，⁹⁰Y，¹¹¹In or¹⁷⁷Lu、¹²⁵I。

As a further preferred embodiment of the present invention, L is selected from the group consisting of azidovaleric acid, propiolic acid, polyethylene glycol, 1,4, 7-triazacyclononane-1, 4, 7-triacetic acid, 7- [ (4-hydroxypropyl) methylene ] -1,4, 7-triazatenonane-1, 4-diacetic acid, 1,4,7, 10-tetraazacyclododecane-1, 4,7, 10-tetraacetic acid, mercaptoacetyltriglycine, MAG2, N3S, N2S 2-type ligands, diethyltriaminepentaacetic acid, 1, 4-succinic acid, 5-aminopentanoic acid, polyethyleneimine, 6-hydrazinopyridine-3-carboxylic acid, benzyl bromoformate, N- (2-aminoacetic acid) maleimide, and combinations thereof.

The L is further preferably one or more of 6-aminocaproic acid, PEG4, PEG 6, HYNIC-PEG4 or HYNIC.

The invention relates to the application of a tumor-targeted probe in preparing a tumor diagnosis reagent; preferably in the preparation of an imaging agent for tumor diagnosis; further preferably in the preparation of a precise localization of tumor boundaries and intra-operative image-navigation imaging agent or in the preparation of a radionuclide imaging agent.

The tumor targeting peptide is applied to the preparation of tumor targeting drug carriers.

The polypeptide can highly simulate the tumor targeting of FGF19 (fibroblast growth factor 19), efficiently combines fibroblast growth factor receptor 4(FGFR4) to a tumor part, has good aggregation and detention at the tumor part, has a higher ratio of target to non-target, is suitable for being used as a fluorescent tumor imaging agent, and can be used for preparing optical imaging medicines for image navigation and accurate positioning of tumor boundaries in tumor operation.

The invention has the beneficial effects that:

1. the invention develops a series of novel high-affinity polypeptides simulating FGF19 (fibroblast growth factor 19) and can be used for targeting fibroblast growth factor receptor 4(FGFR 4). The FGFR4 receptor is highly expressed in tumors, and can be used for early diagnosis of FGFR4 highly expressed tumors based on the principle that YQGF-X (X ═ 1-6) polypeptide is specifically combined with FGFR4 receptor.

2. The polypeptides are low molecular weight polypeptides, the synthesis cost is low, and the series of short peptides introduce unnatural amino acids for modification, so that the stability of the polypeptides in a living body is greatly improved. The circulating time of the polypeptide in vivo is prolonged by prolonging the half-life period of the polypeptide, and the concentration and detention of the image probe at a tumor part are promoted, so that a better tumor imaging effect is obtained, and the polypeptide is more favorable for clinical popularization and application.

3. The peptides are reported for the first time, the preparation method is simple, and the acquisition channel is convenient.

4. YQGF-X (X-1-6) series polypeptide can be specifically combined with tumor cells, and has excellent development effect on various tumors including liver cancer, breast cancer, cervical cancer, colorectal cancer and the like through in-vivo optical imaging and results.

5. The invention has good application prospect in fluorescence imaging and fluorescence guided surgery by utilizing the advantages of deeper penetration depth of the near-infrared fluorescent dye MPA and weaker autofluorescence of background tissues.

6. The YQGF-X (X-1-6) polypeptide radiopharmaceutical can be used for screening and early diagnosis of tumors, and can be used for monitoring early malignant tumors and treating the early malignant tumors in situ in a real-time and nondestructive manner.

Drawings

FIG. 1 shows the structure (A), HPLC analysis chart (B) and MS (C) of YQGF-1 as a targeting compound.

FIG. 2 is a flow cytometry analysis of the affinity of different fluorescent targeting compounds in HepG2 cells.

FIG. 3 is an optical imaging diagram of the fluorescence targeting compound MPA-YQGF-1 in the liver cancer HepG-2 tumor-bearing mouse.

FIG. 4 is an optical imaging diagram of the fluorescence targeting compound MPA-YQGF-2 in vivo of mice bearing tumor of liver cancer SMMC-7721.

FIG. 5 is an optical imaging diagram of the fluorescence targeting compound MPA-YQGF-3 in a mouse with colorectal adenocarcinoma HCT116 tumor.

FIG. 6 is an optical image of the fluorescence targeting compound MPA-YQGF-4 in the mouse with colorectal adenocarcinoma HT29 tumor.

FIG. 7 is an optical imaging diagram of the fluorescence targeting compound MPA-YQGF-5 in the body of a breast cancer MCF-7 tumor-bearing mouse.

FIG. 8 is an optical imaging diagram of the fluorescence targeting compound MPA-YQGF-6 in the mice bearing the tumor of cervical carcinoma Hela.

The specific implementation mode is as follows:

the invention is further illustrated by the following specific examples and application examples: wherein the chemical substances used in the synthesis steps are all the existing substances or commercial products. The polypeptides involved in each example were synthesized by Hangzhou Guotu Biotech Co.

Example 1 the polypeptide YQGF-1 is taken as an example and comprises the following steps:

(1) swelling of the resin

Adding a certain amount of Rink Amide MBHA resin into a reaction column, then adding a proper amount of Dichloromethane (DCM), and slightly blowing nitrogen for 10-30 minutes to ensure that the resin is fully swelled. The dichloromethane solution was drained, washed 3 times with Dimethylformamide (DMF) and drained.

(2) Fmoc removal

A20% solution of piperidine in DMF was added to the reaction column and deprotected once for 5 minutes and once for 8 minutes. After the reaction was complete, the resin was washed 3 times with DMF, DCM, DMF, respectively.

(3) Coupling of

Accurately weighing Fmoc-IIe-OH and O-benzotriazole-tetramethyluronium Hexafluorophosphate (HBTU) which are 3 times of the molar number of charged resin, completely dissolving the Fmoc-IIe-OH and the O-benzotriazole-tetramethyluronium Hexafluorophosphate (HBTU) in DMF, adding N, N-Diisopropylethylamine (DIPEA) to activate carboxyl, adding the solution into a reaction column for reaction, washing the solution for 30 minutes by DMF, DCM and DMF for 3 times in sequence respectively, draining the solvent, and adding a small amount of resin into 6% ninhydrin/ethanol solution and 80% phenol/ethanol solution for detection one drop each. If the condensation is complete and no free amino exists, the solution is colorless or light yellow; otherwise the resin or solution will turn blue or reddish brown indicating incomplete reaction. After the reaction was completed, the reaction mixture was washed with DMF, DCM, and DMF 3 times. Repeating the operation, sequentially coupling other amino acids until the last amino acid Fmoc-His-OH is coupled, washing the obtained peptidyl resin with methanol, and fully drying in a vacuum drying oven.

(4) Cracking

Adding 120mL of lysate (87.5% trifluoroacetic acid, 5% thioanisole, 2.5% ethanedithiol, 2.5% phenol and 2.5% water) into resin, shaking for 2h at low temperature, separating the lysate from the resin by using a sand core funnel, and keeping filtrate. Slowly dripping the filtrate into ice anhydrous ether, and naturally settling for 30min after dripping. Then centrifuging to obtain a solid, washing the solid with diethyl ether for three times, and drying the obtained precipitate to obtain a crude dry powder.

(5) Purification of

Purifying by high performance liquid chromatography with C18 column with chromatographic filler of 10 μ M, gradient elution with 0.1% TFA/water solution-0.1% TFA/acetonitrile solution as mobile phase system, purifying by circulating sample injection, loading crude product solution into chromatographic column, starting mobile phase elution, collecting main peak, evaporating off acetonitrile to obtain target polypeptide concentrate, lyophilizing to obtain target polypeptide, measuring mass-to-charge ratio, and determining molecular weight [ M-H ] to obtain the final product]^-＝930。

EXAMPLE 2 preparation of the polypeptide YQGF-X (X. 2-6)

The tumor targeting peptide YQGF-2, the sequence of which is the polypeptide shown in SEQ ID NO. 2, was prepared according to the method of example 1, and mass spectrometry confirmed [ M-H ]]^-933. Tumor targeting peptide YQGF-3 with the sequence as shown in SEQ ID No. 3, and mass spectrum confirmation of the polypeptide [ M-H ]]^-1953. Tumor targeting peptide YQGF-4 with the sequence as shown in SEQ ID NO. 4, and mass spectrum confirmation of the polypeptide [ M-H ]]^-943. Tumor targeting peptide YQGF-5, which is polypeptide shown in SEQ ID NO. 5, [ M-H ]]^-933. Tumor targeting peptide YQGF-6, which is polypeptide shown in SEQ ID NO. 6, [ M-H ]]^-＝933。

Example 3 preparation of fluorescence targeting Compound MPA-YQGF-1

MPA is an invention patent from our prior application to the subject group, granted patent nos.: CN 101440282.

(1) 0.02mmol of MPA was dissolved in 200. mu.L of ultra-dry DMSO, and 3.7mg of 1-ethyl- (3-dimethylaminopropyl) carbodiimide hydrochloride and 2.2mg of N-hydroxysuccinimide (EDCI/NHS) (molar ratio MPA: EDCI: NHS ═ 1:1.5:1.5) were added and reacted with light for 4 hours to carry out carboxyl group activation reaction.

(2) Taking 0.02mmol of polypeptide YQGF-1(X is 1-6) synthesized by a solid phase, adding 0.1mmol of triethylamine and 200 mu L of ultra-dry DMSO into a 5mL reaction bottle, and reacting for 10min under the protection of nitrogen; adding the solution obtained in the reaction (1) into the reaction solution obtained in the reaction (2), and stirring at room temperature for reaction for 12 hours;

(3) after the reaction is finished, the reaction solution is concentrated by freeze-drying, then distilled water is added for dilution, and separation and purification are carried out by using a preparation liquid phase, wherein the preparation liquid phase conditions are as follows: an Agilent 1220Infinity II series HPLC system was used with an Agilent ZORBAX SB-C18 semi-preparative column (9.4X 250mm, 5um) gradient elution for 60 minutes at a flow rate of 2mL/min, where mobile phase A was ultrapure water (0.01% TFA) and B was acetonitrile (0.01% TFA). The elution gradient was set as: 95% A and 5% B at 0-5 min, 85% A and 15% B at 15 min, 70% A and 30% B at 30min, 50% A and 50% B at 45 min, 10% A and 90% B at 60 min. The final green product was confirmed to be the expected product MPA-YQGF-1 by analytical HPLC and ESI-MS mass spectrometry, see FIG. 1. In the preparation process, YQGF-X (X is 2, 3, 4, 5 and 6) polypeptide synthesized by a solid phase is used for replacing YQGF-1 polypeptide used in the step, and other polypeptide compounds with tumor targeted optical imaging functions, such as MPA-YQGF-2, MPA-YQGF-3, MPA-YQGF-4, MPA-YQGF-5 and MPA-YQGF-5, can be obtained.

The affinity of the compound MPA-YQGF-X (X ═ 1-6) prepared in example 4 for HepG2 cells.

Cultured human liver cancer HepG2 cells were eluted from 12-well plates and resuspended in PBS solution, incubated with MPA-YQGF-X (X ═ 1-6) (10umol/L) prepared in the examples for 2 hours, and their mean fluorescence intensity was measured by flow cytometry, the stronger the fluorescence intensity, the stronger the affinity to the cells was. When the affinity of the probe to the receptor on the cell is strong, the average fluorescence intensity value of the cell detected by the flow cytometer is high, see fig. 2. In vitro affinity assay results show that after the probes of MPA-YQGF-X (X ═ 1-6) at the same concentration were incubated with HepG2 cells highly expressing FGFR4, the affinity strength between YQGF-1 and HepG2 was the greatest, but YQGF-2, YQGF-3, YQGF-4, YQGF-5, and YQGF-6 also had significant affinity compared to the blank control group.

The compound MPA-YQGF-1 prepared in example 5 has an optical imaging picture in liver cancer HepG2 tumor-bearing mice.

The compound MPA-YQGF-1 prepared in example 3 was formulated into a physiological saline solution (1mg/mL), and 3 liver cancer HepG2 tumor-bearing nude mice (body weight: about 20 g) were injected with 15. mu.L of the drug MPA-YQGF-1 solution through the tail vein, respectively, and optical signal acquisition was performed at 0.5h, 1h, 2h, 4h, 6h and 12h after administration. The distribution of the probes in the mice and the enrichment in the tumor area were observed. The imaging results of the compound MPA-YQGF-2 in 3 tumor-bearing nude mice are basically consistent, and the imaging picture of 1h shows that the probe has obvious aggregation in the tumor and clear tumor edge outline until the probe is still retained in the tumor for 12 h. The development results are shown in FIG. 3. Wherein, the probe is most enriched at the tumor site at 2h, and is rapidly absorbed and cleared in other background organs, and the probe is mainly metabolized through the kidney from the signals of the bladder.

The optical imaging of the compound MPA-YQGF-2 prepared in example 6 in mice bearing tumor of liver cancer SMMC-7721.

The compound MPA-YQGF-2 prepared in example 3 was formulated into a physiological saline solution (1mg/mL), and 3 nude mice bearing liver cancer SMMC-7721 tumor (body weight: about 20 g) were injected with 15. mu.L of the drug MPA-YQGF-2 solution through the tail vein, and optical signal acquisition was performed at 0.5h, 1h, 2h, 4h, 6h and 12h after administration. The distribution of the probes in the mice and the enrichment in the tumor area were observed. The imaging results of the compound MPA-YQGF-2 in 3 tumor-bearing nude mice are basically consistent, and the imaging picture of 1h shows that the probe has obvious aggregation in the tumor and clear tumor edge outline until the probe is still retained in the tumor for 12 h. The development results are shown in FIG. 4. Wherein, the probe is most enriched at the tumor site at 2h, and is rapidly absorbed and cleared in other background organs, and the probe is mainly metabolized through the kidney from the signals of the bladder.

Optical imaging of compound MPA-YQGF-3 prepared in example 7 in mice bearing colorectal adenocarcinoma HCT 116.

The compound MPA-YQGF-3 prepared in example 3 was formulated into a physiological saline solution (1mg/mL), and 3 colorectal adenocarcinoma HCT116 tumor-bearing nude mice (weighing about 20 g) were injected with 15. mu.L of the drug MPA-YQGF-3 solution through the tail vein, respectively, and optical signal acquisition was performed at 0.5h, 1h, 2h, 4h, 6h and 12h after the administration. The distribution of the probes in the mice and the enrichment in the tumor area were observed. The imaging results of the compound MPA-YQGF-3 in 3 tumor-bearing nude mice are basically consistent, and the imaging picture of 1h shows that the probe has obvious aggregation in the tumor and clear tumor edge outline until the probe is still retained in the tumor for 12 h. The development results are shown in FIG. 5. Wherein, the probe is most enriched at the tumor site at 2h, and is rapidly absorbed and cleared in other background organs, and the probe is mainly metabolized through the kidney from the signals of the bladder.

Optical imaging of the compound MPA-YQGF-4 prepared in example 8 in colorectal adenocarcinoma HT29 bearing mice.

The compound MPA-YQGF-4 prepared in example 3 was formulated into a physiological saline solution (1mg/mL), and 3 colorectal adenocarcinoma HT29 tumor-bearing nude mice (body weight: about 20 g) were injected with 15. mu.L of the drug MPA-YQGF-4 solution through the tail vein, respectively, and optical signal acquisition was performed at 0.5h, 1h, 2h, 4h, 6h and 12h after the administration. The distribution of the probes in the mice and the enrichment in the tumor area were observed. The imaging results of the compound MPA-YQGF-4 in 3 tumor-bearing nude mice are basically consistent, and the imaging picture of 1h shows that the probe has obvious aggregation in the tumor and clear tumor edge outline until the probe is still retained in the tumor for 12 h. The development results are shown in FIG. 6. Wherein, the probe is most enriched at the tumor site at 2h, and is rapidly absorbed and cleared in other background organs, and the probe is mainly metabolized through the kidney from the signals of the bladder.

An optical image of the compound MPA-YQGF-5 prepared in example 9 in mice bearing MCF-7 tumor with breast cancer.

The compound MPA-YQGF-5 prepared in example 3 was formulated into a physiological saline solution (1mg/mL), and 15. mu.L of the drug MPA-YQGF-5 solution was injected into 3 breast cancer MCF-7 tumor-bearing nude mice (body weight: about 20 g) through the tail vein, respectively, and optical signal acquisition was performed at 0.5h, 1h, 2h, 4h, 6h and 12h after the administration. The distribution of the probes in the mice and the enrichment in the tumor area were observed. The imaging results of the compound MPA-YQGF-5 in 3 tumor-bearing nude mice are basically consistent, and the imaging picture of 1h shows that the probe has obvious aggregation in the tumor and clear tumor edge outline until the probe is still retained in the tumor for 12 h. The development results are shown in FIG. 7. Wherein, the probe is most enriched at the tumor site at 2h, and is rapidly absorbed and cleared in other background organs, and the probe is mainly metabolized through the kidney from the signals of the bladder.

An optical image of the compound MPA-YQGF-6 prepared in example 10 in mice bearing Hela tumor of cervical cancer.

The compound MPA-YQGF-6 prepared in example 3 was formulated into a physiological saline solution (1mg/mL), and 15. mu.L of the drug MPA-YQGF-6 solution was injected into 3 cervical cancer Hela tumor-bearing nude mice (body weight: about 20 g) through the tail vein, respectively, and optical signal acquisition was performed at 0.5h, 1h, 2h, 4h, 6h and 12h after the administration. The distribution of the probes in the mice and the enrichment in the tumor area were observed. The imaging results of the compound MPA-YQGF-6 in 3 tumor-bearing nude mice are basically consistent, and the imaging picture of 1h shows that the probe has obvious aggregation in the tumor and clear tumor edge outline until the probe is still retained in the tumor for 12 h. The development results are shown in FIG. 8. Wherein, the probe is most enriched at the tumor site at 2h, and is rapidly absorbed and cleared in other background organs, and the probe is mainly metabolized through the kidney from the signals of the bladder.